Mounjaro®
Starting from £179.99/mo
Start journey Learn moreCold hands are a real and commonly reported experience for people on Mounjaro (tirzepatide). The sensation usually traces back to reduced peripheral blood flow as the body adjusts to treatment, and it tends to settle over time. It is not listed as a common side effect in the licensed product information, but it is well recognised among people taking GLP-1 and dual-agonist medicines. As with any new symptom that appears after starting or increasing a dose, a prescriber should know about it — especially if it is severe, one-sided, or accompanied by numbness, pain or colour changes in the fingers. Mounjaro is a prescription-only medicine, and the right person to assess whether your particular experience is expected, manageable or worth investigating further is the clinician overseeing your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When you start tirzepatide (or move up to a higher dose) several things shift in the body at once. Appetite drops, so calorie intake falls, and with fewer calories available the body produces less heat. That reduced thermal output tends to show up at the extremities first, because the body prioritises warmth at its core. This is the most straightforward explanation for the cold-hands experience many people describe in the first weeks of treatment.
There is also a circulatory dimension worth knowing about. GLP-1 receptor agonists influence vascular tone, and some researchers have noted modest changes in peripheral blood flow in people taking these medicines. Tirzepatide acts on both the GIP and GLP-1 receptors, which makes its vascular effects slightly more complex than those of a single-agonist. None of this means harm is happening, but it does explain why the sensation can feel more pronounced than you might expect from a weight-loss treatment. The tirzepatide overview on our medicines page covers how the dual-receptor mechanism works in broader terms.
For most people the feeling is bilateral (both hands equally), mild, and gradual in onset. It often peaks in the first two to four weeks after a dose change, then fades as the body adjusts. That pattern alone is reassuring, and worth tracking if you are unsure.
This is the real question, and the honest answer is that it depends on the full picture. Cold hands during Mounjaro treatment, when bilateral, mild and settling, generally fall into the category of an adjustment effect worth watching. Logging when it happens (time of day, which hands or fingers, whether activity or warmth helps) gives your prescriber something concrete to work from rather than a vague report.
The picture changes if any of these apply: the cold is one-sided; fingers turn white, blue or deep red; you have pain or a sharp tingling that does not resolve; or symptoms appeared with no dose change and are getting worse. Those features can point to conditions unrelated to Mounjaro entirely (Raynaud's phenomenon being the most commonly confused one) and they need a proper clinical assessment. You can read about the tingling sensation some people experience in the hands and feet alongside coldness, as the two sometimes appear together.
Separately, dehydration can amplify peripheral coldness. Nausea and reduced appetite sometimes mean people drink less than they should, and poor hydration tightens circulation further. If your fluid intake has dropped since starting treatment, that is worth addressing in its own right, and worth mentioning to your prescriber, since the NHS patient information for tirzepatide notes that staying hydrated is an important part of managing side effects.
You do not have to wait for a formal review to take sensible action. Layering up, keeping hands active and ensuring meals contain adequate protein and fat (not just reduced calories) can all help maintain circulation and body temperature. Some people find that spreading food intake across the day, rather than one or two small meals, reduces the dips in warmth they notice between doses.
Cold hands tend to be more noticeable on the days immediately after injection, when tirzepatide's concentration in the body is rising. Noting whether your coldest periods cluster around injection day can help confirm the connection and give your prescriber a clearer picture, and our page on Mounjaro hands goes into more detail about why the extremities are particularly affected. There is a broader discussion of feeling cold on Mounjaro more generally if the sensation extends beyond your hands.
If you are weighing up whether Mounjaro is the right treatment for you and what to expect from it physically, it is also worth reading about how Mounjaro acts on fat in the body, since understanding the mechanism can help set realistic expectations about physical changes during treatment. The cost and access context page and the treatment overview may also be useful background. And if this symptom is making you reconsider treatment altogether, that conversation is exactly what a prescriber should be having with you, not something to work through alone. At nume, a named clinician reads your consultation, not a piece of software, and aftercare is available seven days a week via our support team if something comes up between reviews.
Most people reporting cold hands on tirzepatide find it manageable and time-limited. But if yours is persistent, worsening, or just worrying you, check your eligibility and speak to our prescribers, it is a straightforward conversation and the right place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.